Prescrire Int. 2002 Dec;11(62):168-9.
(1) Moxifloxacin is the fourth fluoroquinolone to be licensed in France with indications covering ENT and respiratory tract infections. (2) In community-acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis, moxifloxacin seems no more effective than other fluoroquinolones available in France (with which it has not been compared) or the other antibiotics with which it has been compared. (3) Moxifloxacin has the usual adverse effects of fluoroquinolones, but carries a greater risk of QT prolongation than ciprofloxacin, levofloxacin and ofloxacin.
(1) 莫西沙星是在法国获得许可的第四种氟喹诺酮类药物，适应症涵盖耳鼻喉科和呼吸道感染。(2) 在社区获得性肺炎、急性细菌性鼻窦炎和慢性支气管炎急性加重期，莫西沙星似乎并不比法国现有的其他氟喹诺酮类药物（未与其进行比较）或与其进行比较的其他抗生素更有效。(3) 莫西沙星具有氟喹诺酮类药物常见的不良反应，但与环丙沙星、左氧氟沙星和氧氟沙星相比，其导致QT间期延长的风险更高。
